U.S. Physical Therapy, Inc.
NYSE:USPHMedical - Care Facilities
+$0.12 today
- Market cap
- $1.42B
- Beta
- 1.16
- P/E (TTM)
- 810.7
- EPS (TTM)
- $0.08
- Dividend yield
- 2.89%
Volume 0.33M
Average 0.20M
USPH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
U.S. Physical Therapy, Inc.NYSE: USPH
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How USPH compares with its peers on the latest reported figures
- USPH's LTM Mar 2026 research & development of $0 is the 6th highest of the 11 companies compared; the peer median is $9.62M.
- Research & development amounts to 0.0% of revenue for USPH, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $360.26M | +137.9% | +38.9% | — | |
| LTM Mar 2026 | $120.06M | -3.1% | -5.4% | 15.2% | |
| LTM Mar 2026 | $59.27M | +10.2% | +5.8% | 4.3% | |
| LTM Aug 2026 | $19.76M | -5.9% | -10.9% | 2.2% | |
| LTM Jan 2026 | $19.24M | +36.6% | — | 23.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding USPH) | $9.62M | +10.2% | +0.2% | 0.0% | |
Competitors are the stored peer set for USPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 495.02M | 553.14M | 604.8M | 671.35M | 780.99M |
| Cost of Revenue | 377.84M | 441.12M | 483.29M | 547.42M | 623.65M |
| Gross Profit | 117.18M | 112.02M | 121.51M | 123.92M | 157.34M |
| Gross Margin | 23.7% | 20.3% | 20.1% | 18.5% | 20.1% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 46.53M | 46.11M | 0 | 58.29M | 0 |
| Operating Expenses | 46.53M | 55.22M | 69.45M | 60.71M | 76.91M |
| Depreciation & Amortization | 11.59M | 14.74M | 15.7M | 18.68M | 22.39M |
| EBITDA | 85.73M | 76.09M | 74.37M | 86.91M | 109.66M |
| EBITDA Margin | 17.3% | 13.8% | 12.3% | 12.9% | 14.0% |
| Operating Income | 70.65M | 56.8M | 52.06M | 63.21M | 80.43M |
| Operating Margin | 14.3% | 10.3% | 8.6% | 9.4% | 10.3% |
| Interest Income | 0 | 0 | 3.77M | 3.94M | 105K |
| Interest Expense | 942K | 5.78M | 9.3M | 8.02M | 9.46M |
| Other Income / Expenses | 2.55M | (1.23M) | (2.69M) | (3M) | (2.62M) |
| Income Before Tax | 73.2M | 55.57M | 49.38M | 60.21M | 77.81M |
| Pre-Tax Margin | 14.8% | 10.0% | 8.2% | 9.0% | 10.0% |
| Income Tax Expense | 15.27M | 12.16M | 12.16M | 14.61M | 19.81M |
| Net Income | 27.82M | 28.27M | 14.67M | 26.46M | 15.06M |
| Net Margin | 5.6% | 5.1% | 2.4% | 3.9% | 1.9% |
| EPS (Basic) | 4.49 | 3.34 | 1.28 | 1.84 | 1.42 |
| EPS (Diluted) | 4.49 | 3.34 | 1.28 | 1.84 | 1.42 |
| Weighted Avg Shares | 12.9M | 12.99M | 14.19M | 15.06M | 15.18M |
| Weighted Avg Shares (Diluted) | 12.9M | 12.99M | 14.19M | 15.06M | 15.18M |
U.S. Physical Therapy, Inc.
NYSE:USPH
Intrinsic Alpha fair value
Locked
Current Price
$95.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.